COMT Genotype Balancing in the Oral THC–CBD Trial
The trial balanced COMT genotypes across treatment groups to reduce a possible source of variation. That design choice did not establish a genetic test that predicts an individual’s response to cannabis.
How the groups were assembled
Woelfl and colleagues studied sixty healthy male volunteers in four parallel groups of fifteen. Participants received placebo, 800 mg CBD, 20 mg THC, or CBD followed by THC. Each group included five Val/Val, five Val/Met and five Met/Met participants for the COMT Val158Met polymorphism. Allocation used genotype stratification and computer-generated blocks.
Balancing differs from demonstrating an interaction
The investigators sought to limit differences related to dopamine elimination as a competing explanation for treatment comparisons. Equal genotype counts strengthen that particular aspect of balance. They do not show that a treatment effect differed significantly by genotype. A claim of genetic moderation needs an analysis comparing treatment responses across the genetic subgroups, with adequate precision.
What an individual claim would require
The paper’s overall findings did not demonstrate reliable protection from the tested CBD pretreatment. Genotype balancing cannot turn those group results into a prediction of impairment, tolerance or safe dosing for a particular person. The selected male sample, oral sequence and small groups further constrain generalization. A case-specific genetic explanation should not be inferred merely because the protocol mentioned COMT.
Related analysis: the oral CBD pretreatment trial.
Research cited
Woelfl and colleagues (2020). Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. DOI: 10.3389/fpsyt.2020.576877.
